Morgan Stanley Initiates Coverage on AgomAb Therapeutics (NASDAQ:AGMB)

Analysts at Morgan Stanley initiated coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a research note issued to investors on Tuesday, MarketBeat.com reports. The firm set an “overweight” rating and a $28.00 price target on the stock. Morgan Stanley’s target price points to a potential upside of 90.74% from the stock’s previous close.

Separately, Wall Street Zen upgraded AgomAb Therapeutics to a “hold” rating in a report on Tuesday, February 17th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $32.00.

AgomAb Therapeutics Price Performance

Shares of NASDAQ AGMB opened at $14.68 on Tuesday. AgomAb Therapeutics has a one year low of $12.66 and a one year high of $17.45.

Trending Headlines about AgomAb Therapeutics

Here are the key news stories impacting AgomAb Therapeutics this week:

• Positive Sentiment: Major brokerages initiated or reiterated bullish coverage with high price targets that imply large upside vs. the current price — JPMorgan started coverage at “Overweight” with a $32 PT (~+118%). JPMorgan Coverage
• Positive Sentiment: Leerink Partners initiated coverage at “Outperform” with a $36 price target (~+145%), which could attract momentum buying from institutional investors. Leerink Coverage (Benzinga) Leerink Coverage (Zacks)
• Positive Sentiment: Morgan Stanley initiated coverage at “Overweight” with a $28 price target (~+91%), reinforcing analyst-driven upside expectations across the sell-side. Morgan Stanley Coverage
• Neutral Sentiment: Short-interest reports posted large increases in “short interest” for early March, but the published figures are internally inconsistent (showing 0 shares and NaN changes); the data appears unreliable and provides no clear signal on actual short pressure. Investors should treat these short-interest entries with caution until corrected filings are available.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.